Presentazione di PowerPoint

1
Baseline Characteristics of the Patients - Part I
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
2
Baseline Characteristics of the Patients - Part
II
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
3
Discontinuation of Study Medications and Selected
Reasons for Permanent Discontinuation
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
4
Kaplan-Meier Curves for the Primary Outcome in
the Three Study GroupsThe composite primary
outcome was death from cardiovascular causes,
myocardial infarction, stroke, or
hospitalization for heart failure
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
5
Relative Risk of the Primary Outcome and of the
Main Secondary Outcome
The primary composite outcome was death from
cardiovascular causes, myocardial infarction,
stroke, or hospitalization for heart failure.
The main secondary outcome was death from
cardiovascular causes, myocardial infarction, or
stroke, which was used as the primary outcome in
the Heart Outcomes Prevention Evaluation (HOPE)
trial. The P value is for the comparison with
the noninferiority margins
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
6
Incidence of the Primary Outcome, Its
Components, and Death from Any Cause
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
7
Secondary and Other Outcomes
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
8
Relative Risks in Prespecified Subgroups
Comparisons between the telmisartan and the
ramipril group (The risk score from the Heart
Outcomes Prevention Evaluation (HOPE) trial
ranges from 2.350 to 5.928, with higher scores
indicating higher risk. The sizes of the squares
are proportioned to the numbers of events
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
9
Relative Risks in Prespecified Subgroups
Comparisons between the combination-therapy
(telmisartan plus ramipril) group and the
ramipril group(The risk score from the Heart
Outcomes Prevention Evaluation (HOPE) trial
ranges from 2.350 to 5.928, with higher scores
indicating higher risk. The sizes of the squares
are proportioned to the numbers of events
The ONTARGET Investigators. N Engl J Med 2008
Epub on Mar 31
10
Patient Eligibility Criteria - Inclusion criteria
The ONTARGET Investigators. NEJM 2008
Supplementary Appendix
11
Patient Eligibility Criteria Exclusion criteria
The ONTARGET Investigators. NEJM 2008
Supplementary Appendix